Lymphoma cells reprogram their genomes to suppress the production of proteins, rendering them “invisible” to the immune system. Dr. Melnick and his lab have discovered this new cancer mechanism and a new drug that can reverse this effect. It restores the ability of the immune system to track down and destroy the tumor. These findings are important not only to Hodgkin and non-Hodgkin lymphomas but also to solid tumors. Dr. Melnick and his collaborators are working to rapidly translate this novel therapeutic agent to a clinical setting, potentially providing a more cost-effective approach for harnessing the immune system to kill cancer cells.